Episodes
-
In this episode of the Psychedelic Medicine Podcast, L.J. Lumpkin III, MA LMFT joins to discuss the potential of psychedelic medicine in the context of sports psychology. L.J. is a therapist, adjunct professor at Pepperdine University, a coach, author, speaker, and the CEO of Nomad Healing Practices.
In this conversation, L.J. shares his personal experience as an athlete and discusses the difficult transition to a new life once an athleteâs career has concluded. He compares the need to reinvent oneself in this context to ego death and explains how psychedelic-assisted therapy may be helpful for navigating this transition. L.J. also discusses the intense pressure athletes are under to perform, mentioning that the drive to win can often overpower the more basic mode of play at the heart of athleticism. This is an area where he finds ketamine to be a particularly powerful medicine, as its dissociate quality can help athletes tune out the high pressure expectations. L.J. also discusses leveraging the critical learning period provided by psychedelic therapies to institute new healthy habits, something which could benefit athletes both on and off the field.
In this episode you'll hear:
How ketamine-assisted therapy may be able to help athletes with their unique psychological challenges Integrating mindfulness to prepare for psychedelic therapies Leveraging the somatic component of psychedelic therapies to address pain The importance of integration practices and support systems The differences between working with psilocybin versus ketamine Drowning out critics and sports commentary and getting back to basics with the help of psychedelic therapyQuotes:
âIf youâve been paid millions of dollars to hit and be aggressive for so long and thatâs how youâve dealt with your emotionsâand it wasnât a problem because you were being rewarded for itâwhat do you do when youâre not getting rewarded for that anymore? When you have to actually change how you process emotionâthereâs not a playbook for that.â [7:46]
âJust talking about [mental health] and normalizing itâall of a sudden youâre allowed to get help, youâre allowed to heal, youâre allowed to go to practices that have been practiced throughout human civilization. Weâre bringing [psychedelics] back and I think that athletes are the ones who are really going to be the ship of normalization.â [22:38]
âEspecially if youâre off season, those other medicines [besides ketamine] I think theyâre going to be even more helpful because that might encourage the rest, it might encourage being able to connect with family systems. I think for some of the more acute stuff, the ketamine does serve a great purpose in that.â [28:16]
Links:
L.J. on Instagram
L.J. on LinkedIn
Nomad Healing Practices website
Psychedelic Medicine Association
Porangui
-
In this episode of the Psychedelic Medicine Podcast, podcast host Dr. Lynn Marie Morski comes on the mic to provide a five-year update on the podcast and share the changes in the legal landscape of psychedelics in the past half-decade. Lynn Marie Morski, MD, JD is the president of the Psychedelic Medicine Association and host of the Psychedelic Medicine Podcast. She sits on the advisory boards of Psychedelics Today, Cybin, VETS, Inc (Veterans Exploring Treatment Solutions), the Oxenberg Foundation, and the Ketamine Task Force. Dr. Morski is a Mayo Clinic-trained physician in family medicine and sports medicine, as well as an attorney and former adjunct law professor.
In this anniversary episode youâll hear about the legally-accessible forms of psychedelic therapy which have come to prominence as potential mainstream therapeutics in recent years. Dr. Mroski shares Information on the legal adult use framework for psilocybin in Oregon, including licensing, costs, and exclusion criteria. She also discusses programs in Australia and Canada that will allow certain patients to access psychedelic therapies such as psilocybin- and MDMA-assisted therapy. In addition to classic psychedelic medicines, Dr. Morski also shares information on the medicine which is currently most accessible: ketamine. She discusses the difference between S-ketamine and R-ketamine and on-label and off-label uses of this substance. In closing, Dr. Morski presents some of the finer details of the current landscape of insurance coverage for ketamine.
In this episode you'll hear:
The difference between decriminalization and legalization The FDA decision to deny the Lykos Therapeuticsâ new drug application for MDMA-assisted therapy for PTSD The upcoming Colorado psilocybin program Psychiatric licenses to administer MDMA and LSD to patients in Australia The Special Access Program for psychedelic therapies in Canada Legal ketamine access in the United States How the Psychedelic Medicine Podcast chooses guestsQuotes:
âI wanted to focus mostly on what is legal because we know thatâs the way things are going to be the most monitored and therefore safely accessible.â [20:45]
âPeople are in this industry because they want other people to feel better and they want to help and theyâre so generous with their timeâ [25:31]
Links:
clinicaltrials.gov - the place to find information on upcoming clinical trials for psychedelic medicine for which you may qualify
Insurance Coverage for Psychedelic Therapy by Vincent Joralemon
SPRAVATO withMe Patient Support Program
Enthea insurance
Previous episode: How to Choose A Psychedelic Facilitator or Retreat Center with Joël Brierre
Previous episode: Warning Signs When Selecting a Psychedelic Facilitator with Juliana Mulligan
Previous episode: Ketamine Scientific Research with Dr. Jason Wallach
Psychedelic Medicine Association
Porangui
-
Episodes manquant?
-
In this episode of the Psychedelic Medicine Podcast, Dr. David Rabin, MD, PhD joins to discuss whether genes can be predictive of oneâs response to MDMA Therapy. Dr. Rabin, a board-certified psychiatrist and neuroscientist, is the co-founder & chief medical officer at Apollo Neuroscience. In addition to his clinical psychiatry practice, Dr. Rabin is also the co-founder & executive director of The Board of Medicine, and a psychedelic clinical researcher currently evaluating the mechanism of psychedelic-assisted psychotherapy in treatment-resistant mental illnesses.
In this conversation, Dr. Rabin shares his research into epigenetic responses to MDMA-therapy, exploring topics of trauma, gene expression, and personalized, data-driven medicine. He discusses the seminal discovery that trauma can cause epigenetic changes in the structure and function of the cortical system and his own research findings that uncovered a reversal of these changes associated with MDMA-assisted therapy. Dr. Rabin hopes further research in this area may allow for leveraging epigenetic data to determine which psychedelic medicine a particular patient may be most likely to respond to and track how effective a given treatment has been. In closing, he expresses excitement about bringing objective biological precision to mental health treatment, drawing a parallel to the discovery of antibiotics which allowed for much more tailored treatments of infections which has saved countless lives.
In this episode you'll hear:
Response rates to psychedelic-assisted therapy for PTSD versus conventional therapies The consequences of ineffective treatment for PTSD MDMA-assisted therapy as preventative care and the societal cost savings involved Genetics, epigenetics, and gene expression Using epigenetic data from simple saliva swabs to better gauge response to MDMA-assisted therapy for PTSDQuotes:
âMost of the treatments we have available today for PTSDâthat are the FDA-cleared, considered gold standard treatmentsâonly actually induce remission from illness⊠in about 30% of people. So of the 100% of the millions of people every year that are getting treated for PTSD, with the best treatments that we have that are currently available, only 30%âat bestâare getting better long term. Everyone else has a diagnosis of PTSD for life.â [3:55]
âMDMA-assisted therapy for people with PTSD is having an effect thatâs similar to what we saw with the discovery of antibiotics for infection.â [8:07]
âFolks with severe PTSD who went through this trial, when they received MDMA-assisted therapy, [the researchers] saw a statistically significant changeâin terms of repairâof the cortisol receptorâs epigenetic code which reflects improved structure and function of that receptor site. But not only thatâwe saw that the amount that people got better⊠was directly correlated with⊠the amount of remodeling and repair at the receptor site.â [18:36]
âEpigenetic code is actually something that can be modified by experiences in our environment. And traumaâor PTSD diagnoses, a series of significant traumas over timeâcan in fact change epigenetic code of the cortisol receptor gene. And that changes how the cortisol receptor gene gets made, and it changes its function.â [29:52]
âPTSD is a disorder of learned fear. How do we treat PTSD? In animals and humans, we provide the same stimulation that they were getting that they are now afraid of in the context of safety. Thatâs how exposure therapy works, thatâs how MDMA therapy works to some extentâall of these tools and techniques work to treat PTSD effectively⊠in the same way. Itâs called safety conditioning.â [36:48]
Links:
Dr. Rabinâs article: Pilot study suggests DNA methylation of the glucocorticoid receptor gene (NR3C1) is associated with MDMA-assisted therapy treatment response for severe PTSD
Dr. Rabinâs website
Dr. Rabin on LinkedIn
Dr. Rabin on Instagram
Dr. Rabin on Twitter
Apollo Neuroscience website
Psychedelic Medicine Association
Porangui
-
In this episode of the Psychedelic Medicine Podcast, Mark Braunstein, DO joins to discuss the promise and the peril of ketamine. Dr. Braunstein graduated medical school in 1997 then completed a General Psychiatry Residency at the University of New Mexico and then a fellowship in Child and Adolescent psychiatry at Maine Medical Center in 2002. Upon graduation from his fellowship and becoming board certified in general psychiatry he established a private practice in Durango, Colorado where plant medicine became part of his everyday integrative psychiatric practice.
In this conversation, Dr. Braunstein shares some of the developments in the world of ketamine in the past three years since his previous episode, drawing on his own experience providing ketamine-assisted therapies. He stresses issues of grandiosity that can arise both when working with ketamine and when taking the medicineâissues which in the worst case and fuel ketamine use disorders. Dr. Braunstein stresses the importance of clinicians providing ketamine treatments being realistic and upfront about the potential harms of ketamine when advising prospective patients. In closing, he warns against the dangers of being in an echo chamber which reinforces potentially pathological substance use, especially for clinicians in the ketamine space.
In this episode you'll hear:
Why ketamine has an addictive potential and how ketamine addiction presents Ways to treat ketamine use disorder The importance of informed consent What patients should look for when seeking a ketamine provider The importance of ketamine providers working with multiple modalities and having multiple tools in the toolbox besides ketamineQuotes:
âHereâs whatâs scary to me about ketamine: these people that Iâve seen having problems [with ketamine use] are largely lifetime recreational psychedelic/drug users without problems. And these are people who have made it to age fifty, smoking [cannabis], tripping a little bit, their whole life without having a problemâthen at fifty years old, find themselves hooked on something for the first time.â [12:30]
â[Ketamine] is not a microdosing medication⊠There is no such thing as ketamine microdosing. You think of microdosing as sub-perceptual. Everyone that Iâve met thatâs abusing ketamine, it was not a sub-perceptual effectâthey were very much abusing it to have that perceived effect. Maybe not a psychedelic effectâusually an intoxicated wonky effect is what theyâre going for. And people refer to that as microdosing. Itâs not microdosing. Itâs abusing small doses.â [17:11]
âWhat do I see that makes me concerned with someone Iâm talking toâa clinician or a client? That grandiosity. So that gets me concerned right away when I hear about these âdownloadsâ because thatâs where ⊠other psychedelics can have dependency too. You see people ⊠they go for aya ceremonies every week after week after week. So there can be an addiction to the download or to the release.â [34:35]
âThe people I know that have been successful in this line of work (from a patient standpoint), whether theyâre a clinician or not, have been the ones that have embraced the work. And just knowing that this is going to be a process and Iâm in it to win it, for life. Iâm working on myself.â [35:40]
Links:
Dr. Braunstein on LinkedIn
Ketamine Research Foundation website
NeuPath Mind Wellness website
Ketamine Training Center website
Previous episode: Ketamine for Alcohol Use Disorder with Steven Mandel, MD
Previous episode: Avoiding the Traps of Psychedelic Self-Absorption with Adam Aronovich, PhD(c)
Previous episode: Navigating Psychedelic Narcissism with Adam Aronovich
Previous episode: Psychedelic Therapy: Slow Down to Heal Faster with Sunny Strasburg, LMFT
Psychedelic Medicine Association
Porangui
-
In this episode of the Psychedelic Medicine Podcast, Steve Rio joins to discuss 5-MeO-DMT for Trauma and PTSD. Steve is a psychedelic facilitator and Co-Founder of Enfold, which offers a groundbreaking psychospiritual model that combines psychedelic intensives, coaching, and community to help individuals heal trauma and reach their full potential.
In this conversation, Steve shares his journey of how he got into facilitating 5-MeO-DMT experiences and insights on working safely and effectively with this medicine over the course of his practice. He discusses the screening procedure he uses before clearing clients for facilitated 5-MeO-DMT experiences to ensure safety as much as possible when working with this powerful psychedelic. Steve also talks about how he tailors his work with clients based on the state of their nervous system and their unique personality. In closing, Steve emphasizes the somatic quality of 5-MeO-DMT experiences, sharing different types of experiences people typically have on the medicine and how these can best be integrated.
In this episode you'll hear:
Preparation for safe and effective 5-MeO-DMT experiences Stories of transformation following 5-MeO-DMT healing for PTSD and focused integration practices How common 5-MeO-DMT reactivations are, and when they typically happen Issues of spiritual bypassing in underground psychedelic facilitation How to navigate informed consent in the context of facilitating psychedelic experiencesQuotes:
âAt the peak of the 5-MeO experience, there is no mind⊠When people talk about the death and the rebirth experience with 5-MeO, what weâre really talking about is relaxing and essentially dissolving the ego entirely so there is no experience of âyouâ in the experienceâyou become one with the experience. But⊠whatâs possible there is that we then access the nervous system and we see these very dramatic energetic releases and people often are physically reliving traumatic experiences and physically releasing the fight, flight, freeze response that may have happened or not happened.â [6:52]
âTrauma is complex and for some people itâs not that simple. For some people, they go through a six- to twelve-month process after 5-MeO-DMT that is really challenging.â [22:37]
âSo [weâre] helping people⊠build sensitivity in their nervous systemâreconnect with sensitivity and slowing things down and building more awareness and learning how to notice their emotions as sensations in the body before they become thought patterns.â [32:00]
âI think one of the challenges in all of this is that people will lie to you to get to your experience because theyâre desperate for the healing. And you have to be really careful about the conversations you have and asking open-ended questions and really listening to your intuitionâand really being grounded in that.â [40:28]
âWhat weâre doing here I would say thereâs obviously a psychological component to it, but often that happens in the weeks and months afterwards. Whatâs happening here is a much more somatic experience and it can be very confusing and challenging for the mind of a person⊠youâve paid all this money, youâve prepared for weeks and months, youâve been thinking about it, you come have this experience⊠Right after the ceremony for some people, the thought is âwhat just happened?â and âdid anything happen?â and âdid it work?â because thereâs very rarely like an immediate insight on âhereâs how youâre going to make your life betterââthatâs not what comes out of this experience. What comes out of this experience is a dramatic shift in how your body feels and often people will report feeling emotionally lighter or that they lost ten pounds. Itâs hard to explain, but the way peoplesâ eyes light up the day after the ceremony is so differentâlike they often just look different coming in and leaving.â [42:56]
Links:
Enfold Website
Enfold on Instagram
Enfold on YouTube
Still In It: 5-MeO-DMT Stories
Previous episode: Psychedelic Therapy: Slow Down to Heal Faster with Sunny Strasburg, LMFT
Previous episode: Psychedelic Adjunct Series: Somatic Therapy with Jenna Valentine, DACM, LAc
Previous episode: Ketamine-Assisted Psychotherapy for Accelerated Growth with Nick BrĂŒss, EdD, LMFT
Previous episode: When *Not* to Proceed with a Planned Psychedelic Journey with Rick Barnett, PsyD
Psychedelic Medicine Association
Porangui
-
In this episode of the Psychedelic Medicine Podcast, Sunny Strasburg joins to open the conversation of leveraging lower doses of psychedelic substances for more effective healing. Sunny Strasburg, LMFT, a licensed psychotherapist, educator, and pioneering author, specializes in psychedelic therapies and training clinicians to be skilled and trauma-informed psychedelic therapists. As the founder and author of The Theradelic Approach, she equips clinicians with trauma-informed psychedelic-assisted therapy methods, blending IFS, EMDR, archetypal psychology, trauma-informed care, and her extensive experience.
In this conversation, Sunny shares insights drawn from Internal Family Systems (IFS) and explores how these perspectives can help inspire more effective psychedelic work, especially with lower doses. She emphasizes the importance of adequate preparation and not over-valorizing intense psychedelic experiences, noting that these therapies themselves can be traumatic if not handled with care. Sunny also discusses how oneâs own internal protectors have adaptive rolls and display a lot of compassionate intelligence, so even though these parts may initially provide a barrier to deep trauma work, it is important for therapists to work collaboratively with these parts of a clientâs psyche. In closing she talks about how to better set reasonable expectations in group psychedelic therapy and retreat settings, where integration can easily turn into a competition of who had the most intense experience, with things like ego dissolution becoming the barometer for healing.
In this episode you'll hear:
How âprotector systemsâ and ârubber band effectsâ manifest in high-dose psychedelic therapy sessions Uncovering previously unknown traumas during psychedelic therapies and how therapists can be better prepared for this situation How therapists can skillfully work with symbolic material that arises in psychedelic journeys The importance of slowing down and letting the client guide the pace when addressing serious traumas in particular Differences between ketamine, MDMA, and the classic psychedelics in terms of effects on the fear center of the brain Leveraging critical learning periods in therapy to reprocess traumatic memoriesQuotes:
âBeing a trauma therapist, you have to be skilled enough to know what is symbolic in a psychedelic journey, whatâs a literal memory⊠You donât want to do any kind of leading or prompting the client to fill in anything or directing them to anythingâyouâre really tracking where they are and letting them uncover their own path. Again, at the speed in which their protector system is ready for that.â [22:43]
âThese parts want people to remember. They want to heal, they want to let their stories be told. And so our job as therapists is to clear the clutter so we can really hear the system and trust the system. The system knows.â [28:02]
âTrauma is like a sliver thatâs buried in the armâlike in the deep skin of your arm and itâs got an infection around it. And all of your coping mechanisms, all of your protectors (using IFS language), is like building a giant layer of scar tissue on top of that. And you could just go through life with that, and you could just put lotion on the top of that scar and just try to make it look prettyâand thatâs okay. But you could go in and surgically remove the sliver thatâs been offending your system the whole time. And once you remove that sliver, you will start to healâyour arm will heal, it wonât have an infection anymore, right? But removing that sliver hurts. Itâs painful. Itâs a process. But you donât have to deal with that sliver anymore. And thatâs kind of how I imagine going through trauma work.â [31:08]
âIâve had clients that Iâve worked with using EMDR, IFS for years, weâve made some progress, but then we get ketamine on board and itâs totally helped them and amplified the benefit.â [35:13]
âTrust your protector system. Slow down. I promise, if you slow down and really get curious about what your protectors need, you will go so much further with these medicines. It really is not a race. Itâs slow and steady, and youâre going to be able to get more work done.â [40:23]
Links:
Sunnyâs website
Sunny on LinkedIn
Sunny on Instagram
Previous episode: Ketamine-Assisted Psychotherapy for Accelerated Growth with Nick BrĂŒss, EdD, LMFT
Psychedelic Medicine Association
Porangui
-
This episode of the Plant Medicine Podcast welcomes Dr. Angela Carter (they/them) to discuss the intersection of the LGBTQIA2S+ community and psychedelics. Dr. Carter is a queer, transgender, and genderqueer naturopathic primary care physician who also works as a midwife, sexual assault examiner, and health equity advocate in Portland, Oregon. They also serve as both the vice-chair and the equity in training subcommittees co-chair of the Oregon Psilocybin Advisory Board. In addition to these positions, Dr. Carter serves as the chair of the Transgender Health Program Community Advisory Board at Oregon Health & Science University. They also volunteer with many organizations including the Fireside Project, Black Rock City Emergency Services, and Queerdome.
Dr. Carter begins this conversation by sharing exciting new research currently being conducted which involves LGBTQIA2S+ individuals and psychedelic therapies. While this particular area of research remains small, it is growing and the fruits of these studies will be an important step for better understanding how these new therapies can serve gender and sexuality minorities, and help facilitators understand the unique concerns of people in the LGBTQIA2S+ community. Dr. Carter illustrates these types of concerns by discussing the prevalence of gender binaries within psychedelic spaces. They describe how in a clinical setting it is prevalent to have both a male and a female facilitator, but this leaves no room for gender-nonconforming people to guide experiencesâsomething which could be preferable if the patient themselves shares this identity.
Dr. Carter also discusses this gender binary in traditional contexts. It is common for ayahuasca ceremonies to provide separate spaces for men and women, again leaving no space for gender-nonconforming people. This reification of the gender binary and the often patriarchal organization of the ayahuasca ceremony can have serious impacts on the set and setting, especially for people in the LGBTQIA2S+ community. Dr. Carter emphasizes the importance of making space for folks in the community so that they are able to receive therapy, attend ceremonies, and participate in integration with others who share similar identities. This shared identity, they emphasize, ensures that LGBTQIA2S+ people donât feel out of place in contexts that ought to be healing. Dr. Carter closes by discussing how members of the LGBTQIA2S+ community experience disproportionate rates of mental illness, further illustrating the crucial importance of equity in accessing psychedelic medicine.
In this episode:
Problems of representation and access for LGBTQIA2S+ individuals in the psychedelic space Current research being done on the intersection between psychedelic therapies and unique issues faced by gender and sexuality minorities Preparations to take before guiding a psychedelic experience for LGBTQIA2S+ people, particularly if you do not come from the community How plant medicines could have unique benefits for the LGBTQIA2S+ community Issues of poverty faced by marginalized peoples and how to support equity of access to emerging psychedelic therapiesQuotes:
âFor some people that idea of melding, of becoming one and losing all of those unique pieces of themselves, doesnât fit their paradigm of a spiritual connecting experience.â [10:47]
âItâs precious, that centering of our communityâto be able to sit with people who just understand.â [19:42]
âPsychedelics offer the opportunity for connection of the self to something greater, something outside, a bigger community, spirituality, and really do a huge amount to heal peoplesâ relationships with substances.â [25:20]
âMarginalized communities have been really impacted, largely, by the war on drugs, which has put millions of people in jail for drug offenses and stolen their ability to make income, stolen their ability to connect with community and we really need to heal that.â [33:34]
Links:
Chacruna Institute Queering Psychedelics 2019 Conference
Queerdome on Facebook
Portland Psychedelic Society
Psychedelic Medicine Association
Porangui
-
In this episode of the Psychedelic Medicine Podcast, Dr. Hans Eriksson joins to discuss the potential of non-dissociative ketamine. Dr. Eriksson, Chief Medical Officer at HMNC Brain Health, is a highly respected drug developer and clinical psychiatrist with over 20 years of pharmaceutical experience. Prior to HMNC Brain Health, Dr. Eriksson served as Chief Medical Officer at COMPASS Pathways and previously as Senior Director of Clinical Research at Lundbeck and Medical Science Director at AstraZeneca.
In this conversation, Dr. Eriksson shares what inspired him to move from clinical practice to drug development, and why he sees so much potential in developing non-dissociative forms of ketamine. He discusses the ways the dissociative effects of ketamine decrease the accessibility of this treatment due to the fact that these changes in perception are undesirable for a significant portion of patients. Dr. Eriksson also shares results from preliminary studies of non-dissociative ketamine which showed efficacy in inducing anti-depressant effects. In closing, Dr. Eriksson discusses why he thinks the experiential element of the classical psychedelics play an important role in their efficacy as mental health treatments, but why this might not be the case when it comes to ketamine.
In this episode you'll hear:
The history of ketamine The pharmacology of ketamineâs dissociative effect The relationship between ketamine dose and antidepressant effect The possibility of bladder issues and addiction with ketamine and whether non-dissociative forms of ketamine would also have these potentials How Dr. Eriksson thinks about combining psychotherapy with ketamine treatmentsQuotes:
âWe are aiming for a similar exposure to the drug as you achieve with, for instance, an intravenous administration, but we are achieving a much lower peak concentration, maximum concentration of the compound. So that is one of the characteristics of our formulation.â [10:58]
âOur view is that it's probably better to try to use the metabolism in the body as a tool to achieve very low exposure to ketamine but high exposure to the downstream metabolites.â [23:19]
Links:
Dr. Eriksson on LinkedIn
HMNC Brain Health on LinkedIn
HMNC Brain Health website
Previous episode: Potential Benefits of Non-Hallucinogenic Psychedelics with Kurt Rasmussen, PhD
Psychedelic Medicine Association
Porangui
-
In this episode of the Psychedelic Medicine Podcast, Chandra Khalifian, PhD joins to explore ketamine-assisted couples therapy. Dr. Chandra Khalifian is a clinical psychologist, researcher, educator and Co-CEO of Enamory, a clinic and community focused on providing expansive relationship education and therapy including psychedelic-assisted couple-therapy.
In this conversation Dr. Khalifian explores the intricacies of ketamine-assisted couples therapy, sharing why she thinks psychedelics, and ketamine in particular, could be a good fit for couples therapy. She discusses the various contexts where ketamine-assisted therapy may be a good fit for couples pursuing therapy, the therapeutic modalities well-suited to this work, and the different dosing and administration routes of ketamine. In closing, Dr. Khalifian explores situations where couples may be better suited to pursuing this therapy individually and also contexts where ketamine-assisted couples therapy would not be an appropriate intervention.
In this episode you'll hear:
How Dr. Khalifian got involved in couples therapy The various models of ketamine-assisted couples therapy, and how to decide what is most appropriate The importance of preparation and integration How to navigate the two people in the couple having very different ketamine experiences When Dr. Khalifian uses intramuscular ketamine infusions versus ketamine lozenges Why Dr. Khalifian leans towards using third-wave cognitive behavioral therapy for ketamine-assisted therapy The tendency for people to make major relationship decisions following intense psychedelic experiencesQuotes:
âKetamine is great becauseâin the same way with individualsâwith couples itâs going to pull us out of that pattern so that we can then see the pattern and talk about the pattern from this observer perspective rather than being stuck in the âitâs me versus youâ we can look at it together and the couple can say âah, thereâs that thing that we do when we feel distressed, and now we can work together on that thing since we can see it from a little more distance.ââ [4:43]
âSimilar to MDMA, people are less likely to express criticisms in a hurtful way and less likely to receive constructive criticism and be defensive [during ketamine therapy].â [9:05]
âI had one couple [as patients for ketamine therapy] that the partner was like âI just felt this liquid compassion. I finally understood why she was engaging in these behaviors. And so everything made sense and I was able to talk about it in a different way.ââ [17:49]
Links:
Enamory website
Enamory on Instagram
Previous episode: MDMA-Assisted Couples Therapy with Kayla Knopp, PhD
Psychedelic Medicine Association
Porangui
-
In this episode of the Psychedelic Medicine Podcast, Dr. Evan Cole Lewis joins to explore the topic of psychedelics and seizure disorders. Dr. Lewis is a Canadian Neurologist and holds an appointment as Assistant Professor in the Department of Paediatrics at the University of Toronto. He has special interest in the treatment of neurologic disorders, including functional seizures, with psychedelic therapies.
In this conversation, Dr. Lewis shares his expertise on a number of topics at the intersection of psychedelics and seizure disorders. He discusses the neurology behind psychedelics and functional neurological disorders more broadly, explaining why he thinks this is a very promising area of research. He explains that currently very little is known about the topic of psychedelics and seizure disorders, as almost all studies have had epilepsy as an absolute contraindication, leaving researchers with only case reports. However, there are some promising indications in the preclinical data which warrant further investigation. In closing, Dr. Lewis sheds light on potential seizure risks resulting from interactions between psychedelics and other medications.
In this episode you'll hear:
The different between epileptic seizures and functional seizures How Dr. Lewis started exploring the topic of psychedelics and functional seizures Why Dr. Lewis thinks psychedelic science has the potential to rebuild bridges between neurology and psychiatry Dr. Lewisâ experiences treating epileptic patients with ketamine The potential for co-administered lithium and psychedelics to cause seizuresQuotes:
âI tell people psychedelics are brain network medicineâthey kind of dissolve those networks. If the thinking is that FND [Functional Neurological Disorder] is due to dysfunctional connection or hyperconnectivity in certain networks, what we have to do is we have to repair those networks, but first we have to take them apart and build them back up.â [11:03]
âRegardless, even if there isnât even a condition in which psychedelics are utilized in neurology, we need the neurologists to be able to indicate that these patients are safeâor at least do the work and be involved in the clinical team.â [21:05]
âThings like drug interactions we pick up with psychedelics again are going to be a big piece of the puzzle that needs to be answered going forward.â [29:17]
Links:
Dr. Lewis on LinkedIn
Dr. Lewis on YouTube
Exploring psychedelic-assisted therapy in the treatment of functional seizures: A review of underlying mechanisms and associated brain networks by Dr. Lewis et al.
Case report: Improvement in refractory functional seizures, depression, and quality of life with ketamine assisted-therapy by Dr. Lewis et al.
Psychedelics, epilepsy, and seizures: a review by Dr. Lewis et al.
Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review by Kelan Thomas, Benjamin Malcolm, et al.
Psychedelic Medicine Association
Porangui
-
In this episode of the Psychedelic Medicine Podcast, Dr. Jenna Valentine joins to explore the intersection of psychedelics and somatic therapy. Dr. Valentine is a doctor of Chinese Medicine who incorporates both functional medicine and somatic experiencing within her practice to help achieve optimal wellness.
In this conversation, Dr. Valentine introduces somatic therapy, drawing parallels to psychedelic work and exploring how this modality may support more healthy and holistic psychedelic experiences. She explains how somatic therapy proceeds by tuning into the body, with therapists helping to guide clientsâ awareness of the intelligence in their bodies.
Dr. Valentine emphasizes the importance of not forcing things in somatic work - with gentler, slower practices often being best to align with health. In closing, she outlines how somatic therapy can be used for preparation and integration of a psychedelic experience, and also explores the possibilities of somatic modalities being used during psychedelic therapy.
In this episode you'll hear:
The different forms of somatic therapy The overemphasis on the mind in our culture Why there arenât contraindications for somatic therapy Somatic therapy as a modality for working with patients diagnosed with biploar disorder or schizophrenia The intersection of healing and re-learning to be playful The importance of âdoing lessâ Why glorifying âheroic dosesâ of psychedelics can be counterproductive to healing Shadow work and somatic therapyQuotes:
âThereâs many different definitions of [somatic therapy] but the one I love the most is: guiding yourself back to your body as your primary resource.â [4:02]
âA lot of the work is making sure people learn that they donât have to feel afraid of themselvesâno part of you is âcoming to get youâ ⊠no part of you is trying to trick you or hurt you or surprise you. Sometimes Iâll describe it as Iâm helping people guide themselves back to themselves and find a safe home there again.â [13:05]
âWe have lost our relationship with discomfort, and a lot of this work is uncomfortable. And the work is being in the discomfort and building a larger capacity for being uncomfortable, and learning the difference between uncomfortable and unhelpful, because thatâs not something weâre trained in.â [23:41]
âThereâs learning that can happen in everything ⊠The expectation is to have no expectation: we can have a loose intention, and then let the body lead.â [47:18]
Links:
Dr. Valentine on Instagram
Dr. Valentineâs website
Psychedelic Medicine Association
Porangui
-
In this episode of the Psychedelic Medicine Podcast Tommaso Barba joins to explore the topic of psychedelics for sexual functioning and intimacy. Tommaso is a PhD candidate at the Centre for Psychedelic Research at Imperial College London where his research is focused on understanding the potential role of psychedelic drugs for well-being. Tommaso authored the first paper on the effects of psychedelics on sexual functioning.
In this conversation, Tommaso shares results from the multiple studies into psychedelics and sexual functions he has been involved in. He reports that in both a trial comparing psilocybin and escitalopram and a survey of naturalistic psychedelic use, respondents reported positive impacts on sexual functioning following psychedelic experiences. He also speculates about aspects of the psychedelic experience that are interpreted as âeroticâ in the midst of the altered state and the reported shifts to experiencing sexual connection as more âspiritualâ following psychedelic experiences. In closing, Tommaso discusses the promise of psychedelic journeys for healthy couples and the difficulties of researching this topic since there is no clear pathology being addressed.
In this episode you'll hear:
How Tommaso got interested in the intersection of psychedelics and sexual functioning Why SRRIs often have side effects of inhibiting sexual function How psychedelic neuropharmacology may help explain improved sexual functioning following psychedelic experiences The upcoming studies exploring the effects of psychedelic journeys on couples who undergo the experience together The possible differences between MDMA and classic psychedelics in terms of mechanism and impact when it comes to effects on sexual functionQuotes:
âWhen we looked at the positive affect symptomsâlike wellbeing, connectedness, ability to feel emotions, and so on⊠Psilocybin outperformed escitalopram. And given so, we were really curious to investigate further the sex lives of these patients, because an active sex life is a key component of peopleâs wellbeing, and a very overlooked one.â [7:34]
âWhat we found was that people treated with psilocybin reported improvements in sexual pleasure, in capacity to communicate sexual desires with their partner, in sexual arousal, sexual satisfaction, and similar components of sexual functioning, while people treated with escitalopram did not report any of these changes and tended to report deterioration in this aspect of functioning.â [11:10]
â[These psychedelic treatments may] work because it disentangles couples and its capable of individuating the two patients into the context of their relationship so that they start to develop a better identity in the context of the relationship instead of being completely fused into each other and not capable of really developing themselves and communicating their desires and what they want.â [31:15]
Links:
Tommaso on Twitter
Tommaso on LinkedIn
Imperial College Centre for Psychedelic Research online survey study: psychedelics and couples
Previous episode: Microdosing and the Placebo Effect with BalĂĄzs Szigeti, PhD
Psychedelic Medicine Association
Porangui
-
In this episode of the Psychedelic Medicine Podcast Kayla Knopp joins to explore the topic of MDMA-Assisted Couples Therapy. Dr. Kayla Knopp is a clinical psychologist and researcher specializing in non-traditional couples and relationships. She specializes in making couple therapies more inclusive, accessible, and effective, including MDMA- and ketamine-assisted couple therapy.
In this conversation, Dr. Knopp introduces MDMA-assisted couples therapy, discussing why this entactogen is a good fit for couples therapy. She discusses how MDMA helps couples explore issues by dissolving typical defensive boundaries and encouraging empathy. She emphasizes that not all couples may be a good fit for this therapy, however, and especially cautions against couples therapy in contexts of abuse where connecting with resources for safety and pursuing individual courses of therapy is more appropriate. In closing, Dr. Knopp discusses the importance of screening and the responsibility the psychedelic community has to ensure these substances are being used in safe and effective therapeutic contexts overseen by qualified and caring facilitators.
In this episode you'll hear:
The history of MDMA-assisted couples therapy When couple therapy is and is not appropriate Integrating MDMA-assisted therapy with cognitive-behavioral conjoint therapy for PTSD Therapeutic modalities which may be well-suited to MDMA-assisted couples therapy
Quotes:
â[MDMA] does so many things that are facilitative of the primary goals of couples therapy, which are to reduce defensiveness, to increase the flexibility that we have in taking our partnerâs perspective, increase the empathy and intimacy we feel with other people, increase the reward that we get from positive interpersonal interactions.â [4:33]
âWhen we treat relationship dysfunction, we know mental health often improves as a result of that and conversely, we also know that sometimes when we do mental health treatments, if we ignore the relational context that somebody is living in, we only give them part of what they need in order to fully heal psychiatrically. So, couple-based interventions for mental health disorders, including PTSD, are up-and-coming as a really effective way to address mental health concerns.â [8:14]
âMDMA tends to increase our window of tolerance for emotional experiencesâit makes it safer and easier for us to remain in contact with feelings that might otherwise feel pretty overwhelming.â [23:48]
âI think thereâs absolutely a lot of ego and a toxic guru model that can show up in psychedelic-assisted therapy that, as a community, as practitioners, as participants, we need to keep an eye out for and keep ourselves accountable as a community to make sure that weâre not giving folks a pass.â [31:17]
Links:
Dr. Knopp on Instagram
Enamory website
Enamory on Instagram
Previous episode: Avoiding the Traps of Psychedelic Self-Absorption with Adam Aronovich, PhD(c)
Psychedelic Medicine Association
Porangui
-
In this episode of the Plant Medicine Podcast, Dr. Mark Braunstein returns to discuss potential concerns surrounding the use of ketamine, especially use which is not overseen by a knowledgeable medical professional. Dr. Braunstein is a whole-health psychiatrist with 22 years of clinical experience. He is the medical director for multiple mental health and psychedelic psychotherapy clinics in Colorado, New Mexico, and Utah and he also runs in-patient and out-patient programs for addiction. Additionally, Dr. Braunstein is involved in multiple projects focused on expanding access, awareness, research, and safety in the field of psychedelics.
To begin this conversation, Dr. Braunstein shares how his original exposure to ketamine wasnât in a medicinal context, but rather as a recreational drug of abuse. However, since then he has seen the transformative effects this substance can have on patients when used in a physician-directed context and for therapeutic purposes. Nonetheless, Dr. Braunstein stresses that this does not mean ketamine use does not come with certain risks.
Ketamine can be addictive and even carries a risk of overdose, particularly when used recreationally in a context where the purity of the substance is unknown. Dr. Braunstein distinguishes recreational and therapeutic uses of ketamine, explaining that recreational doses are often lower and dosing is more frequent, whereas ketamine is used in high doses in a therapeutic context, with extended periods between sessions.
Dr. Braunstein stresses both the responsibility of physicians and of patients to ensure ketamine is prescribed responsibly and used as directed. Despite the dangers posed by recreational ketamine use Dr. Braunstein describes in this conversation, it is still a medicine he believes can have significant positive impacts for patients. This requires, however, that it not be treated merely as yet another quick fix pill. Instead, Dr. Braunstein emphasizes that ketamine treatment ought to coincide with psychotherapeutic work. This combination, he says, will maximize the therapeutic potential of ketamine while also helping to ensure that the medicine is used responsibly, under the close direction of a medical professional.
In this episode:
The addiction and overdose potential with recreational ketamine use How dosage can dramatically change the effects of ketamine Responsible prescribing practices for physicians working with ketamine The psychological and physiological harms of ketamine abuse How Dr. Braunstein talks to his patients about responsible use before prescribing ketamine The importance of combining psychedelic medicines with psychotherapeutic workQuotes:
âPart of why ketamine works is because it lights up your brain in all these different ways and when done occasionally, intentionally, it moves you. But if youâre always doing that, it ends up having the reverse effect, causing damage.â [12:56]
âThis is a heavy-duty medication that, if you cross the line, can cause you to stop breathing and then die. So there is an actual, real danger to ketamine.â [16:25]
âI think the organ that is most prone to damage from overuse of ketamine is the same organ we are touting it fixing: the mind.â [18:39]
âWhen we think about these medications, we should think about combining them with therapy and not just taking these medications as medications⊠So thatâs why with ketamine Iâm really recommending it with therapy.â [25:04]
Links:
Reconscious Medical
Psychedelic Medicine Association
Porangui
-
In this episode of the Psychedelic Medicine Podcast we discuss the topic of psychedelics and postpartum mood disorders. Melissa Whippo is a licensed psychotherapist who specializes in the intersection of women's health and psychedelics. She founded a non-profit, Deva Collective, which has fiscal sponsorship with MAPS, and is currently conducting research about perimenopause and microdosing San Pedro.
In this conversation, Melissa shares the details of existing research into psychedelic treatments for postpartum populations. She discusses the findings from her study on âThe Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women,â reporting that ketamine was not detected at all in breast milk twelve hours after dosing. She also shares information on parentsâ intentional use of microdosing and what motivates them to take up this practice. In closing, Melissa discusses her upcoming research on microdosing San Pedro among perimenopausal populations and why she decided to focus on San Pedro for this study.
In this episode you'll hear:
The early research into ketamine for postpartum depression and whether ketamine remains in breast milk The prevalence of mood concerns in the postpartum population Issues of access with ketamine treatments for new mothers Improvements in postpartum mood patients following ketamine treatments that Melissa has seen in her practice Hormone changes after giving birth and how this might relate to mood concerns Ketamine for postpartum painQuotes:
âThe reason why ketamine and other psychedelics appeal to me more [than other treatments for postpartum depression], is itâs not a medicine you have to take every day and itâs not a medicine thatâs going to cause a significant separation [with the newborn] like a hospital admission would.â [5:55]
âMore SSRIâwhich is still considered safe by the medical professionâpasses through the breastmilk than ketamine. Probably nanograms. And ketamine has such a short half-life in the system, particularly with the intramuscular route of administration, that twelve hours after dosing, the breast milk was completely clear.â [14:22]
âThatâs what ketamine does so wellâit gives people a different view of some of the things theyâre really struggling with that they canât quite break through. Some of these more recursive ruminations that seem to befall mothers quite a bitâand theyâre usually pretty negative. But the medicine space gives them a different view.â [18:52]
Links:
Melissaâs study: The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women: Quantification of Ketamine and Metabolites
Melissaâs article in the Washington Post: Some moms are microdosing mushrooms for anxiety and depression
Melissaâs website
Deva Collective website
Melissa on Instagram
Plant Parenthood website
Previous episode: Psychedelics and Womenâs Health with Allison Feduccia, PhD
Psychedelic Medicine Association
Porangui
-
In this episode of the Psychedelic Medicine Podcast, Hannah Raine-Smith and Jocelyn Rose join to discuss the psychedelic assisted EMDR therapy. Hannah is an integrative psychotherapist and independent researcher specializing in psychedelic integration using EMDR therapy. Jocelyn is a research therapist working on psychedelic clinical trials. She also works in private practice, and has a special interest in exploring the unfolding potential of EMDR as a scalable, trauma focused psychedelic assisted therapy.
In this conversation, Hannah and Jocelyn introduce the basics of eye movement desensitization and reprocessing (EMDR) therapy and its possible utility in adjunct to psychedelic assisted therapies. They discuss the overlapping mechanisms between EMDR and psychedelic therapies, with both engaging the serotonin 5-HT2 system and promoting neuroplasticity. Hannah and Jocelyn explain their excitement around integrating EMDR with psychedelic therapy, stressing that this may make these treatments more accessible for the patients who could benefit most from psychedelic therapy. In closing, the researchers call for additional investigation of the intersection of psychedelic therapy and EMDR and invite collaboration from anyone else exploring these promising treatments.
You can contact Hannah and Jocelyn at [email protected]
In this episode you'll hear:
How EMDR works to help people process traumatic memories Similar neurological effects of psychedelic therapies and EMDR Understanding the adaptive information processing (AIP) framework Hannah and Jocelynâs novel hypothesis for the basis of hallucinogen persisting perception disorder (HPPD) Using EMDR as an integration therapy for past psychedelic experiences Making psychedelic treatments more accessible and inclusiveQuotes:
âLike with indigenous shamanic practices, EMDR uses simple rhythms to alter consciousness. So EMDR is like an ancient healing mechanism thatâs been adapted to treat the modern soul.â [4:56]
âWhen we reprocess these memories using bilateral stimulation of the brain, you start thinking and feeling differently about the same events. So trauma therapy isnât about changing the past, itâs about how you think and feel about those experiences.â [5:26]
âSome of the resistance that would normally be present in an EMDR session is diminished when someone has had a recent psychedelic experience.â [12:02]
âResearch has shown that EMDR taps into the same mechanisms as REM [sleep]. Itâs like adding the healing benefits of dreaming whilst on psychedelics but being more in control of what gets reprocessed.â [14:42]
âThe people who are most likely to have adverse drug reactions to psychedelicsâwhether thatâs HPPD or toleranceâtend to be the people who also have adverse childhood experiences or have traumatic complexity in their biographical content. And so we recognize that thereâs a need for trauma-focused psychedelic treatments if weâre going to make these treatments available to the people who need them most and make them scalableâand we think EMDR is a good enough fit for that work to happen.â [25:46]
Links:
Hannah and Jocelynâs article: âPsychedelic-assisted EMDR therapy (PsyA-EMDR): A memory consolidation approach to psychedelic healingâ
Bridge to the Matrix: A Memory Consolidation Approach to Psychedelic Healing website
Hannah on LinkedIn
Jocelyn on LinkedIn
Previous episode: Ketamine-Assisted Psychotherapy for Accelerated Growth with Nick BrĂŒss, EdD, LMFT
Psychedelic Medicine Association
Porangui
-
In this episode of the Psychedelic Medicine Podcast, Steven Radowitz, MD joins to discuss the state of the research into ketamine treatments for PTSD. Dr. Steven Radowitz is the Chief Medical Officer and Co-Founder, Nushama. He believes psychedelic medicineâs framework of neuroscience, mystical experience, and integration therapy is the future of mental wellness, and current solutions often fall short, treating symptoms without addressing underlying issues. Dr. Radowitz and the Nushama team have administered thousands of ketamine journeys for mood disorders and are known to be best-in-class and among the most experienced globally.
In this conversation, Dr. Radowitz shares the journey of his career in medicine and how he got involved in the treatment of mood disorders with ketamine. He discusses the way he works with patients to determine the best dosing of ketamine for their unique therapeutic needs and the way dosage intersects with the durability of the changes. Dr. Radowitz emphasizes how ketamine promotes neuroplasticity, which allows patients with PTSD to open a critical response window when confronted with triggers and re-code memories of trauma. In closing, Dr. Radowitz discusses the importance of integration and highlights the way psychedelic therapies empower patients to be their own healers.
In this episode you'll hear:
Using both psycholytic and psychedelic doses of ketamine and how therapeutic approach differs between the two Stories of transformation from Dr. Radowitzâs ketamine practice The practices Dr. Radowitz recommends for patients following ketamine infusions How Dr. Radowitz uses music in his ketamine practiceQuotes:
âAs much as we segregate all these mood disorders into separate disease entities⊠thereâs actually a common seed for them allâthereâs just different manifestations. But I say about 95% of the people who come in here [for ketamine treatments] have some type of trauma.â [4:56]
âThe dose doesnât always correlate with the experienceâit usually doesnât. I can give people the same dose, with the same music, same everything, and they'll have completely different experiences each time.â [13:23]
âWhat we do here is to create a medically safe and an emotionally safe environment for [patients]. But the medicine is themâtheyâre the therapists in the end. ⊠I want them to realize itâs all coming from them. They have everything they need within themselves to heal.â [32:15]
Links:
Nushama website
Nushama on LinkedIn
Nushama on Instagram
Nushama on Facebook
Nushama on TikTok
Dr. Radowitz on Linkedin
The Untethered Soul: The Journey Beyond Yourself by Michael A. Singer
Letting Go: The Pathway of Surrender by David R. Hawkins
Psychedelic Medicine Association
Porangui
-
In this episode of the Psychedelic Medicine Podcast, Rick Strassman, MD joins to discuss the topic of endogenous DMT. Dr. Strassman is adjunct associate professor of psychiatry at the University of New Mexico in Albuquerque and author of DMT: The Spirit Molecule and The Psychedelic Handbook. His DMT and psilocybin studies in the early 1990s initiated the renewal of human research with psychedelics in the U.S.
In this conversation, Dr. Strassman discusses the finer details of DMT, from endogenous production in humans and animals, to visionary experiences and theological implications. Dr. Strassman also covers the research that's been done regarding endogenous DMT, clarifying what we do and donât know about the role of the pineal gland and how this might relate to what is reported during near-death experiences. He also discusses the personal and relational quality of psychedelic experiences induced by DMT, mentioning that unitive mystical experiences were actually rare in the trials he conducted, with more experiences having a personal quality, drawing upon the life experiences and interests of the participants. In closing, Dr. Strassman shares his thoughts on the origins of the visions that many report during DMT use.
In this episode you'll hear:
The overlap between psychedelic experiences and meditation techniques The relationship between fear, self-awareness, and difficult DMT experiences The placebo effect and psychedelic research Dr. Strassmanâs thoughts on non-hallucinogenic psychedelics DMT as a possible treatment for strokes to prevent damage and speed recovery Effects of microdosing in animals and humansQuotes:
âI think the best term for these compounds is psychedelic, which means mind manifesting or mind disclosing, because only one of our fifty-five or so normal volunteers had what one might call a mystical unitive state. ⊠Everybody basically had an experience that was totally dependent on them. It was not inherent in the drug.â [9:45]
âYou could still speculate that to the extent that non-drug states resemble those brought on by giving DMT⊠that DMT plays a role in the production of those states. But the data aren't there yet. That's why we need more people doing this research.â [24:16]
âIf psychedelics are super placebos and if we have a psychedelic drug in our brain, it's attempting to speculate that normally the placebo effect could be mediated by endogenous DMT.â [27:42]
âIf you starve neurons of oxygen they start dying, but if you add DMT they survive much longer. So there seems to be some neuroprotective effect of DMT on ischemic damage to neurons, at least in the test tube.â [32:27]
Links:
Dr. Strassmanâs website
The Psychedelic Handbook by Dr. Strassman
DMT: The Spirit Molecule by Dr. Strassman
DMT and the Soul of Prophecy: A New Science of Spiritual Revelation in the Hebrew Bible by Dr. Strassman
Dr. Strassman on Facebook
Previous episode: Exploring DMT Entities with Matthew Johnson, PhDPsychedelic Medicine Association
Porangui
-
In this episode of the Psychedelic Medicine Podcast, Stephanie Knatz Peck, PhD joins to discuss the research on psilocybin for anorexia nervosa. Dr. Stephanie Knatz Peck is a clinical psychologist and Associate Clinical Professor at the University of California, San Diego with an expertise in eating disorders. She conducts clinical research on novel treatments for eating disorders and has been involved with clinical research evaluating psychedelics across a variety of mental health indications in the capacity of researcher and therapist. She also published the first ever report on a clinical study evaluating psilocybin for anorexia nervosa.
In this conversation, Dr. Peck discusses the difficulties of treating eating disorders and the emerging evidence around the safety and efficacy of psychedelic-assisted therapies for these conditions. She discusses the results from a study she conducted on the safety and tolerability of psilocybin therapy for females with anorexia nervosa, finding that the treatment was safe and generally well tolerated amongst the trial group. The study additionally found positive treatment outcomes following the psilocybin therapy in a number of participants. In closing, Dr. Peck discusses how psychedelics are able to open a âbehavior change windowâ following dosing sessionsâsomething which may be crucial to their efficacy in treating eating disorders.
In this episode:
Dr. Peckâs work treating patients with eating disorders The lesser known diagnostic categories orthorexia and eating disorder not otherwise specified (EDNOS) Genetic predisposition for eating disorders Why the participants in Dr. Peckâs study thought they could benefit from additional psilocybin dosing sessions How transformative psychedelic experiences can help shift values and identities to promote eating disorder recoveryQuotes:
âWe think that there are specific personality features that predispose someone to engage in dietary restrictive processes or behaviors or actions or modify their lifestyle around exercise and foodâand then they fall into anorexia. And the thing that distinguishes those people is that sometimes they have these predisposing factors like a lot of anxiety or preoccupation, an ability to be highly self disciplined⊠Thereâs a lot of processes in place that can cause a diet to go awry and turn into anorexia.â [12:29]
âSomething that distinguishes anorexia from other psychiatric illnesses is that it is an illness that really results in a lot of physiological vulnerabilityâacross all body systems. And so while it might be fine to just assume that with some other psychiatric illnesses we can reliably assume safety, with this particular population thereâs cardiac issues, thereâs serotonergic things that affect cardiac issues that we really needed some safety data on.â [19:13]
âWe really need better treatments [for eating disorders] that treat from the inside out, meaning like what is happening on an underlying psychological level, neuropharmacological level, thatâs causing someone to want to engage in these behaviors and I think that is the value of these [psychedelic] treatments is that we are treating from a different direction.â [27:25]
Links:
Dr. Peckâs study: Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study
Current eating disorder studies at UCSD
BrightMind Therapy website
Dr. Peck on Twitter
Psychedelic Medicine Association
Porangui
-
In this episode of the Psychedelic Medicine Podcast, Ben Malcolm, PharmD, MPH joins to discuss why he prefers the term âpsychosomatodelicsâ for psychedelics. Dr. Malcolm is a psychopharmacology consultant, psychedelic educator, founder of Spirit Pharmacist, LLC and a board member of the Psychedelic Medicine Association.
In this conversation, Dr. Malcolm shares the meaning of the term psychosomatodelic as well as the history of the different terms used to refer to psychedelics. He emphasizes the ways that these substances manifest mind and body together, rather than only focusing on the mind-altering aspects of the experience. He also suggests that the line between side effects and therapeutic opportunities is blurry in psychedelic therapy, discussing the ways in which nausea and purging in the context of ayahuasca ceremonies can contribute to the sense of healing and psychosomatic catharsis. In closing, Dr. Malcolm suggests some directions for future research regarding serotonergic psychedelics' interaction with the gut-brain axis and the autonomic nervous system.
In this episode:
The meanings of more newer, more specified terminology such as psychoplastogen, entactogen, and more Trauma-resolving aspects of psychedelic experiences How psychedelics impact transmodal cortices of the brain The somatic side effects of psychedelicsQuotes:
âThe psychedelic experience is inherently larger than either brain or mind, and itâs more of a mind-body kind of experience. And it would be worth recognizing the mind-body contribution that is happening as far as the types of experiences persons are having, and maybe even the ways that psychedelics are working to provide a true, felt sense of relief for persons.â [3:51]
âWhy do we wear a blindfold for psychedelic therapy? Well, youâre actually trying to limit the sensory input from certain unimodal sensory cortices like vision and youâre trying to amplify sensory contentâmaybe from the body, maybe from the viscera, maybe from inside. Itâs to heighten the internal landscape. Thatâs why youâre actually shutting out these kinds of external sensory inputs.â [17:19]
âParticularly if youâre approaching psychedelics for healing of trauma, then thinking of them as energetic purgatives that have a psychosomatodelic, or full mind-body manifesting type of experience, might allow you to wrap your head around the psychedelic experience or what its doing a little bit easier.â [31:53]
Links:
Spirit Pharmacist website
Spirit Pharmacist on Facebook
Spirit Pharmacist on Instagram
Spirit Pharmacist on YouTube
Previous episode: Medical Literature Regarding Psychedelics, Pregnancy, and Breastfeeding with Ben Malcolm, PharmD
Psychedelic Medicine Association
Porangui
- Montre plus
